While travel and face-to-face interaction may not be safe or even possible, biotech, pharma, and financial attendees can still access the unparalleled partnering and content offered by ChinaBio® Partnering Forum, BioPharm America™ and BIO-Europe® in August, September and October, either as individual conferences, or with a Virtual Passport to all three, at a substantially reduced fee.
8 Global events
11,644 Executive-level attendees attracted
48,347 One-to-one partnering meetings held
6,673 Attending companies
60 Countries represented
12,193 Licensing opportunities on offer
The Covid-19 pandemic is creating unprecedented healthcare challenges with far reaching effects yet to be measured. There is a need for greater collaboration and communication among researchers, healthcare systems, government agencies, NGOs, and the public at large. Behind the scenes, the biopharma industry is rallying to innovate and collaborate to develop diagnostics, vaccines and treatments as quickly as possible.
Industry leaders in China share insights from the outbreak and highlight the opportunities and challenges ahead, including what strategies can be deployed to prepare for the future. Key learnings will be discussed to determine the best path forward as we work towards a new normal.
Ninety-five percent of VCs add zero value to a startup other than cash, said tech venture capitalist Vinod Khosla. He explained that about four out of every five VCs actually damage their own investments with bad advice.
So who out there is more than just a checkbook? Which VCs bring value to the table, in the form of useful introductions or strategy?
We consistently provide valuable in-depth insight and analysis on the most recent trends in life science and partnering. Don't miss the latest releases!
partneringONE is even more powerful than before. New features and functionality will increase your productivity and improve your partnering experience. Look out for a mobile-responsive platform, time-saving message templates and enhanced search capabilities and collaboration tools.
FIND OUT MORE
Our network of more than 40,000 high-value dealmakers, companies and assets from around the world are looking for "best-fit" partners.
Find out moreFacilitating strategic connections
that drive life science dealmaking.
